Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.62 |
| ▸ | NAAA | Q02083 | 3/20 | 0.62 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.49 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3770457 | 1.00 | CCR2 (0.62) | CCR2NAAACRBNNOD1GNAI3 | |
| SCHEMBL3766769 | 1.00 | CCR2 (0.62) | CCR2NAAACRBNNOD1GNAI3 | |
| SCHEMBL3776092 | 1.00 | CCR2 (0.62) | CCR2NAAACRBNNOD1GNAI3 | |
| SCHEMBL3775239 | 1.00 | CCR2 (0.62) | CCR2NAAACRBNNOD1GNAI3 | |
| SCHEMBL19359368 | 0.99 | CCR2 (0.60) | CCR2NAAACRBNNOD1 | |
| SCHEMBL19370805 | 0.99 | CCR2 (0.60) | CCR2NAAACRBNNOD1 | |
| SCHEMBL30080349 | 0.93 | CRBN (0.53) | CCR2NAAACRBN | |
| SCHEMBL26318101 | 0.93 | CRBN (0.53) | CCR2NAAACRBN | |
| SCHEMBL30080223 | 0.93 | CRBN (0.53) | CCR2NAAACRBN | |
| SCHEMBL26318088 | 0.93 | CRBN (0.53) | CCR2NAAACRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1980237-B1 | GELLING AGENT | AJINOMOTO KK (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-7850955-B2 | contain a specific N-acylamino acid monoamide monoalkyl ester; do not cause sweating while retaining a practical level of gel strength; good spreadability, and good fittability to skin; antiperspirants | AJINOMOTO CO., INC. (JP) | 2010-12-14 | — | — | US | disclosed |
| CN-101365415-A | Gelling agent | AJINOMOTO KK (JP) | 2009-02-11 | — | — | CN | disclosed |
| US-20080311164-A1 | GELLING AGENT | AJINOMOTO CO. INC (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1980237-A1 | GELLING AGENT | Ajinomoto Co., Inc. (JP) | 2008-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311164-A1 | GELLING AGENT | CUTA, NAAA, ASIC1 | CCR2 4262/4885NAAA 2/4885CRBN 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.